Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absent, aforementioned, Albuferon, allege, alleged, alleging, analyzed, appealing, ascending, assumption, award, Bayer, Benefical, Boston, BRIT, budget, Carolina, CED, cediranib, Celldex, cilengitide, complaint, condensed, CT, CTL, daily, decline, deficiency, demostrated, disputed, encompassing, fifteen, GAAP, GCP, gemcitabine, great, guided, Harmonization, ICH, immunocytokine, immunosuppressive, improperly, India, ineffective, infrequent, interfered, interfering, kilogram, led, lessen, load, log, MAb, melanoma, microbubble, mild, missile, MRI, Nexavar, nil, Orange, outsourcing, ovary, peak, peptide, pharmacologic, point, precision, predicated, problematic, proportion, RECIST, recovered, relapse, replase, repurchase, RNA, robust, saving, secret, serum, simplified, slightly, South, stressful, technique, telaprevir, transient, ultrasound, undefined, undergoing, unrecognized, vaccine, valopicitabine, Vectibix, violation, weekly, yield
Removed:
abnormal, allocated, allocation, antidilutive, attendance, attributed, canceled, closely, conversion, converted, create, detachable, earliest, embedded, EMEA, Equiplace, exploring, feature, finder, forced, guidance, implementation, injected, interim, issuable, Medicinal, merged, negotiated, NeoPharm, panitumumab, paper, plc, prominent, quotient, resale, rollforward, SPA, split, tarvacin, transition, TransMID, unamortized, unique, unused, voluntary, Xenova
Filing tables
Filing exhibits
Related press release
CDMO similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-130271, 333-121334, 333-106385, 333-57046, and 333-17513; Form S-3 Nos. 333-139975, 333-132872, 333-128322, 333-121450, 333-109982, 333-103965, 333-99157, 333-71086, and 333-40716) of Peregrine Pharmaceuticals, Inc. of our reports dated July 9, 2007, with respect to the consolidated financial statements and schedule of Peregrine Pharmaceuticals, Inc., Peregrine Pharmaceuticals, Inc. management's assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Peregrine Pharmaceuticals, Inc., included in the Annual Report (Form 10-K) for the year ended April 30, 2007.
/s/ Ernst & Young LLP
Orange County, California
July 9, 2007